The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma.
BCLC
ERBB3
HCC
biomarker
Journal
Biology
ISSN: 2079-7737
Titre abrégé: Biology (Basel)
Pays: Switzerland
ID NLM: 101587988
Informations de publication
Date de publication:
11 Mar 2021
11 Mar 2021
Historique:
received:
08
02
2021
revised:
03
03
2021
accepted:
08
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Epidermal growth factor receptor 3 (ERBB3) is a surface tyrosine kinase receptor belonging to the EGFR/ERBB family, involved in tumor development and progression. We evaluated the diagnostic and prognostic value of serum ERBB3 measurement in hepatitis C virus (HCV)-infected patients with early hepatocellular carcinoma (HCC). A total of 164 HCV-infected patients (82 with cirrhosis and 82 with early HCC) were included in the study. HCC was classified according to the Barcelona Clinic Liver Cancer (BCLC) staging system. Among patients with HCC, 23 (28%) had a diagnosis of very early tumor (BCLC = 0), while 59 (62%) had a diagnosis of early HCC (BCLC = A). Median overall survival (OS) in patients with HCC was 79.2 (95% CI 51.6-124.8) months. While ERBB3 serum values were similar between patients with cirrhosis and those with HCC (
Identifiants
pubmed: 33799723
pii: biology10030215
doi: 10.3390/biology10030215
pmc: PMC7999043
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : University of Turin
ID : #ABAM_RILO_20_01
Références
Cancers (Basel). 2019 Nov 20;11(12):
pubmed: 31756933
Cancer Biomark. 2018 Feb 14;21(3):603-612
pubmed: 29278878
Methods Mol Biol. 2018;1655:319-334
pubmed: 28889394
Cancer Res. 2019 Apr 15;79(8):1831-1843
pubmed: 30733195
Hepatol Int. 2017 Jul;11(4):317-370
pubmed: 28620797
Hepatology. 2020 Dec;72(6):2206-2218
pubmed: 32064645
Methods Mol Biol. 2017;1652:3-35
pubmed: 28791631
Oncogenesis. 2020 Feb 13;9(2):16
pubmed: 32054828
Liver Int. 2015 Aug;35(8):2027-35
pubmed: 25495478
Mol Cancer Res. 2018 Oct;16(10):1579-1589
pubmed: 29934326
J Natl Cancer Inst. 2013 Feb 20;105(4):266-73
pubmed: 23221996
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
J Exp Clin Cancer Res. 2016 Aug 11;35(1):126
pubmed: 27514687
Cancer Sci. 2020 May;111(5):1500-1513
pubmed: 31997489
Pol Arch Med Wewn. 2014;124(6):329-35
pubmed: 24781707
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Sci Rep. 2018 Sep 18;8(1):13978
pubmed: 30228363
Hepatology. 2006 Jun;43(6):1303-10
pubmed: 16729298
Aliment Pharmacol Ther. 2009 Jul;30(1):37-47
pubmed: 19392863
PLoS One. 2015 May 22;10(5):e0128159
pubmed: 26000702
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
Panminerva Med. 2017 Dec;59(4):320-331
pubmed: 28880053
Tumour Biol. 2016 Jan;37(1):857-63
pubmed: 26254096
Oncotarget. 2016 Jul 5;7(27):41677-41690
pubmed: 27223437
Cancers (Basel). 2020 Sep 28;12(10):
pubmed: 32998218
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
J Proteome Res. 2011 Oct 7;10(10):4715-24
pubmed: 21877752
Int J Mol Sci. 2019 Mar 18;20(6):
pubmed: 30889843
Panminerva Med. 2018 Dec;60(4):185-191
pubmed: 29856183
F1000Res. 2016 May 12;5:
pubmed: 27239288
Am J Pathol. 2019 Oct;189(10):1898-1912
pubmed: 31351986
Int J Epidemiol. 2021 Mar 3;50(1):128-142
pubmed: 33349860
PLoS One. 2020 Mar 25;15(3):e0222259
pubmed: 32210440